Overview Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Status: Not yet recruiting Trial end date: 2024-12-30 Target enrollment: Participant gender: Summary Phase 1/2 trial to study the safety, pharmacokinetics and preliminary efficacy of BN301 given intravenously every 3 weeks. Phase: Phase 1/Phase 2 Details Lead Sponsor: BioNova Pharmaceuticals (Shanghai) LTD.